ACMELAB The Acme Laboratories Limited
Pharmaceuticals & Chemicals
Tk 79.5 as of 2026-11-12 14:05:46
Data completeness 100%
Score breakdown
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency EPS grew in 3 of 4 years
- Consistency Paid a dividend every year (5/5)
- Profitability Net profit growing 11.54% a year
- Valuation P/E 6.28 is low (general benchmark ≤ 12)
- Valuation Trades near book value (P/NAV 0.57x)
- Valuation Price is 60% below the Graham fair value (Tk 199.2)
- Ownership Institutions (30.55%) hold more than the public (29.03%)
Concerns
- Profitability Average ROE only 9.97% (below 10%: capital not working hard)
Notes
- Solvency Debt/equity 0.84x (well managed)
Risk flags
No flags raised.
Valuation
52-week range
15.9% above the low, 10.4% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
Dividends and safety
Size, liquidity and ownership
Shareholding
- Sponsor/director 40.4%
- Institution 30.6%
- Foreign 0%
- Public 29%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | 7.42 | 95.04 | 157 | 25 | 0 |
| 2022 | 9.98 | 102.5 | 211 | 30 | 0 |
| 2023 | 10.89 | 110.09 | 230 | 33 | 0 |
| 2024 | 11.61 | 118.39 | 246 | 35 | 0 |
| 2025 | 11.48 | 126.37 | 243 | 35 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 147.5%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.